UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant To Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report: April 8, 2015
(Date of earliest event reported)

COHBAR, INC.

(Exact name of registrant as specified in its charter)

Delaware	**000-55334**	**26-1299952**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

1455 Adams Dr., Suite 2050
Menlo Park, CA 94025
(Address of principal executive offices and zip code)

(415) 388-2222
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

COHBAR, INC.
FORM 8-K

Item 7.01 Regulation FD Disclosure

On April 8, 2015, Cohbar, Inc. (the "Company") posted a presentation titled, "Meeting with Investors" on its website, www.cohbar.com, under the heading "Investor Relations." The presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The presentation provides an overview of the Company's strategy, research and future objectives. The presentation is intended to be made available to shareholders, analysts and investors, including those participating in a meeting with the Company's management to be held on April 8, 2015.

The information in this Item 7.01 and in the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:

99.1 CohBar, Inc., "Meeting with Investors," dated April 8, 2015.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COHBAR, INC.
(Registrant)

April 8, 2015
(Date)

By: /S/ Jeffrey F. Biunno
Jeffrey Biunno
Chief Financial Officer

Exhibit 99.1

Meeting with Investors
Vancouver, B.C.
April 8, 2015

Legal Disclaimer

This presentation includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future plans, intentions, expectations, business prospects and opportunities. Examples of such forward-looking statements include: statements regarding our research plans and timelines, anticipated outcomes and timing of our research programs, IND-enabling activities and pre-clinical and clinical trials for our MBTs; expectations regarding the future market for any drug we may develop; expectations regarding the growth of MBTs as a significant future class of drug products; statements regarding the anticipated therapeutic properties of our MBTs; expectations regarding our ability to effectively protect and expand our intellectual property; statements concerning perceived competitive advantages and our ability to defend competitive advantages; and expectations regarding our ability to attract and retain qualified employees and key personnel. These statements reflect management's current beliefs and are based on information currently available to management. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements including, but not limited to, our ability to retain key personnel, expand our research operations and successfully advance our research programs. Although the forward-looking statements contained in this presentation are based upon what management believes to be reasonable assumptions, management cannot assure that actual results will be consistent with these forward-looking statements. Investors should not place undue reliance on forward-looking statements. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. The forward-looking statements and other information contained in this presentation are made as of the date hereof and CohBar, Inc. does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Live Longer, Live Well (video clip)

American Federation for Aging Research (AFAR) www.afar.org

Agenda

- **Live Longer, Live Well -** ***AFAR Video***
- **Introductions -** ***Albion Fitzgerald (Chairman)***
- **How to die young at a very old age -** ***Nir Barzilai (Founder)***
- **Break**
- **CohBar Science -** ***Ken Cundy (CSO)***
- **CohBar Business -** ***Jon Stern (CohBar CEO)***

The Founders

Pinchas Cohen, MD

- Dean of the Davis School of Gerontology at the University of Southern California
- Executive Director of the Ethel Percy Andrus Gerontology Center
- William and Sylvia Kugel Dean's Chair in Gerontology
- Recipient of numerous awards for research, including the *National Institute of Aging "EUREKA"-Award,* the *NIH-Director-Transformative RO1-Grant* and the *Glenn Award for Research in Biological Mechanisms of Aging*
- Dr. Cohen holds an MD degree from the Technion Israel Institute of Technology
- Postdoctoral training at Stanford University

Nir Barzilai, MD

- Dr. Barzilai is the Director of: the Institute for Aging Research, the Paul F. Glenn Center for Biology of Human Aging Research and the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging
- Recipient of the *Beeson Fellowship for Aging Research*, the *Ellison Medical Foundation Senior Scholar in Aging Reward*, the *Paul F. Glenn Foundation Award*, the *NIA Nathan Shock Award* and the *2010 Irving S. Wright Award of Distinction in Aging Research*
- Dr. Barzilai holds an MD degree from the Technion Israel Institute of Technology

John Amatruda, MD

- Former SVP and Franchise Head for Diabetes and Obesity at Merck Research Laboratories where he lead the development and regulator approvals of Januvia and Janumet for Type 2 Diabetes
- Previously Dr. Amatruda founded and managed a drug discovery group at Bayer Corporation, where he was VP and Therapeutic Area Research Head for Metabolic Disorders research

David Sinclair, PhD

- Professor in the Genetics Department at Harvard Medical School, Co-Director of the Paul F. Glenn Laboratories for Biological Mechanisms of Aging and a Professor in the Physiology and Pharmacology Department at the University of New South Wales
- Co-founder of Sirtris Pharmaceuticals (NASDAQ:SIRT) and Genocea Biosciences (NASDAQ:GNCA)

Management

Jon Stern, MBA Chief Executive Officer	• Senior business executive with over 30 years of diversified management experience • COO of The Key Worldwide, EVP of Integrated China Media and VP of IMC, a division of Kaufman and Broad, CEO and Founder of Cine Coasters, Inc., acquired by division of Liberty Media • B.S. in Business Administration from The University of California, Berkeley • MBA from Marshall School of Business at the University of Southern California
Kenneth Cundy, PhD Chief Scientific Officer	• Joined CohBar in November 2014 as Chief Scientific Officer (CSO) • CSO and SVP for Xenoport, Inc. (NASDAQ:XNPT) • Senior director of biopharmaceutics at Gilead Sciences • Principal research investigator at Sterling Drug, a division of Eastman Kodak • B.S. in pharmacy from the University of Manchester • Registered as a pharmacist in the UK • Ph.D. in pharmaceutical sciences from the University of Kentucky • Postdoctoral training in biochemistry at the University of California, Berkeley
Jeffrey Biunno, CPA Chief Financial Officer	• 25 years of experience with small, medium and large capitalization companies • CFO of Manage IQ (acquired by Red Hat) • VP & Controller of Dialogic and VP & Controller of Novadigm, Inc. (NASDAQ:NVDM) • MBA from Montclair State University • Certified Public Accountant, licensed in the State of New Jersey

Board of Directors

Albion Fitzgerald Chairman	• Over 45 years of experience in the technology sector • Member of the board of directors since May 2014 and appointed chairman in July 2014 • Previously CEO and Chairman of ManageIQ, Inc., Co-Founder, CEO and Chairman of Novadigm, Inc. (NASDAQ: NVDM) and Founder and CEO of Telemetrix, Inc.
Marc Goldberg Director	• Joined the board of directors in November 2014 and Managing Director at BioVentures Investors (life science focused venture and private equity investment firm) • Previously on the board of directors of Enanta Pharmaceuticals (NASDAQ: ENTA), President & CEO of the Massachusetts Biotechnology Research Institute, founding President of the Massachusetts Biotechnology Council and VP, Finance & Corporate Development, CFO and Treasurer of Safer, Inc. • AB (Harvard), JD (Harvard Law School) and MBA (Harvard Business School)
Jon Stern Director	• Joined the board of directors in May 2014
Nir Barzilai, MD Director	• Co-founder and has served on the board of directors since 2009
Pinchas Cohen, MD Director	• Co-founder and has served on the board of directors since 2009

How to Die Young at a Very Old Age

CohBar Founder

Nir Barzilai M.D.
Professor of Medicine and Genetics
Director: Institute for Aging Research
PI: Glenn Center for the Biology of Human Aging
The Nathan Shock Center of Excellence in the Biology of Aging
Albert Einstein College of Medicine

Aging is the major risk factor for death from all chronic diseases



Source: NIH

What is the evidence for success in the goal of delaying aging?



- Healthy life-span has been extended by genetic (GH/IGF-1), environmental and drug interventions in numerous models
- Relevant drugs have been used in humans (Metformin, Acarbose, Rapalogs, etc.)
- **Aging is not an FDA indication**

Do humans age at different rates?

Lifespan vs. Healthspan



Graph ©Mark Collins-Glenn Foundation

Exceptional and Healthy Longevity

Irving Kahn (video clip)

http://www.einstein.yu.edu/centers/aging/longevity-genes-project/

Centenarians end-of-life medical costs are Significantly lower



Centers for Disease Control: Most Recently Available Data

Centenarians: Interaction with the environment (n=477, 75% female)

'Environmental' risk	Centenarians Men	Women
• Overweight/obese:	48%	44%
• Smoking:	60%	30%
• Alcohol (daily):	24%	12%
• Physical activity, (walking, bicycling, housework)	43%	47%
• Vegetarians: 2.6%		

Swapnil Rajpathak, Jill Crandall, J Am Geriatr Soc. 2011 Aug 3

Jay Leno – Tonight Show (Video Clip)

http://www.nbc.com/the-tonight-show/classic/jay-leno/episodes

Offspring are less likely to have age-related diseases than controls



JAGS 2004; 52:274

Diminished GH/IGF-1 and longevity (led to the founding of CohBar)

Small dogs live longer than large dogs



Longer lifespan in daf-2 mutants

Ghr$^{-/-}$, *lit/lit*, GHA, Wt, bGH

↑ Longevity ↓

Ponies live longer than thoroughbreds

Genotyping IGF1R Mutations 700 subjects revealed 9 centenarians vs. 1 control (~2%) harbor nonsynonymous mutations ($p<0.02$) and carriers have higher IGF-I (($p<0.04$) and tend to be shorter. PNAS-….Barzilai &Cohen….

Genome of mitochondria and mitochondrial-derived peptides (MDPs): A New Untapped Field in Biology



Cell Membrane



mitochondria

CohBar: From the DNA of the Nucleus to the DNA of the mitochondria

nucleus

Mitochondria: Overview

Originally a bacteria, helped survive oxidative environment and provides for energy (ATP)!



Mitochondrial function declines with age

Mitochondrial dysfunction is common in many diseases (i.e. diabetes and neurodegeneration)

Mitochondria are key to cell energy, metabolism & life-cycle

Humanin: The First Mitochondrial Peptide



24 amino acid peptide transcribed from within the mitochondrial DNA

- Produced from the mitochondria
- Expressed and secreted
- Present in tissues
- Detected in spinal fluid, and Plasma
- Protects against cell death and Alzheimer's
- Regulator of glucose metabolism


Frieda's 100 birthday: Humanin levels over 2000!

Humanin as an indicator of healthy aging

Humanin declines with aging but is higher in offspring of centenarians when compared to an age and gender matched control group

Humanin is lower in humans with poor endothelial function, a major risk factor cardiovascular diseases

Offspring with Familial Exceptional Longevity



Humans with Normal Endothelial Function



Questions?

CohBar Science

Ken Cundy (Chief Scientific Officer)

Mitochondrial Biology and Genomics

Mitochondria are components within the cell that produce energy and regulate cell death in response to signals received from the cell.

Mitochondrial Genomics:

- Mitochondria are the only cell components besides the nucleus that have their own DNA.
- Until recently, scientists believed the mitochondrial genome contained only 37 genes.
- Research by our founders has revealed that the mitochondrial genome has dozens of distinct new genes that encode peptides (small amino acid chains), which we refer to as Mitochondrial-Derived Peptides, or "MDPs."

MDP's – A New Untapped Field of Biology

MDP's are a diverse and largely unexplored collection of peptides with potentially beneficial biological effects.

MDP Biological Effects:

- Influence cellular activities by acting as messengers between cells, triggering intra-cellular changes
- Metabolic effects, neuro-protective effects, cyto-protective effects and anti-inflammatory effects
- Humanin, the first MDP discovered in 2001 by Dr. Cohen (CohBar co-founder) and others:
  - has protective effects in various animal models of Alzheimer's disease, atherosclerosis, myocardial and cerebral ischemia, and Type 2 Diabetes

CohBar Founders' MDP Discoveries

MDP's have the potential to lead to novel mitochondria-based therapeutics (MBTs) for a number of diseases with significant unmet medical needs.

1. **MOTS-c**
   - Plays a significant role in regulation of metabolism
   - Potential source of MBTs to treat Type 2 Diabetes, obesity, and fatty liver.

2. **SHLP-6**
   - Suppresses cancer progression in mice
   - Potential source of MBTs to treat prostate and breast cancer

3. **SHLP-2**
   - Protects neuronal cells from toxicity in vitro
   - Potential source of MBTs for the treatment of Alzheimer's disease.

4. **Humanin/Humanin Analogs**
   - Effective in animal models of Type 2 Diabetes, neurodegeneration, etc.
   - Potential source of MBTs to treat a variety of diseases

MDP Optimization and Development into Mitochondria-Based Therapeutics (MBTs)

CohBar MBT Optimization Process:

- Synthesis of analogs of native MDP
- Physicochemical Properties
  - Solubility
  - Chemical stability
- Resistance to Enzymatic Degradation
  - Stability in tissues
- Efficacy
  - In vitro cell-based assays
  - In vivo disease models
- Pharmacokinetics
  - Half-life, distribution, elimination



CohBar MDP: MOTS-c
A Key Regulator of Metabolism



CohBar MDP: MOTS-c

The Company plans to advance research on MOTS-c and novel MBT analogs of MOTS-c as our lead program, which we believe has the potential to lead to a commercially successful drug for the treatment of type 2 diabetes, obesity, and other indications.



MOTS-c reverses age-dependent insulin resistance in mice



MOTS-c prevents weight gain in mice on a high fat diet

CohBar MDP: SHLP-6

The Company plans to advance its research on SLHP-6 and novel MBT analogs of SHLP-6 with the potential for the treatment of cancer.



SHLP-6 blocks tumor growth by killing cancer cells and reducing their blood supply

R

CohBar MDPs – Diseases and Patents

The Company has developed an IP position and operational plan intended to allow for proprietary exploitation and protection of its drug candidates:

			Therapeutic Activities / Method of Use Claims						
	Granted / Filed	Composition Claims	Type 1 Diabetes	Type 2 Diabetes	Obesity	Fatty Liver	Cancer	Alzheimer's	Atherosclerosis
MOTS-c	Filed	✓	✓	✓	✓	✓	✓		
SHLP-6	Filed	✓					✓		
SHLP-2	Granted	✓	✓	✓				✓	
Humanin Analogs	Granted	✓		✓					
Humanin Analogs	Two Granted		✓						
Humanin & Humanin Analogs	Filed								✓

***CohBar** is the **exclusive licensee** from the Regents of the University of California and the Albert Einstein College of Medicine to four issued US patents and four US and international patent applications directed to compositions comprising MDPs and MDP analogs and methods of their use in the treatment of indicated diseases.*

CohBar's Targets – Large Medical Needs

The Company's drug discovery efforts are centered on the identification of MDPs that have potential for further development as MBT drug candidates for these major diseases:

Type 2 Diabetes and Obesity – The World Health Organization ("WHO") reports that over 346 million people worldwide suffer from diabetes, of which 90% is Type 2 Diabetes.

Cancer – WHO estimates that in 2012, there were 14.1 million new cancer cases diagnosed, 8.2 million cancer deaths and 32.6 million people living with cancer worldwide.

Alzheimer's Disease – The Alzheimer's Association® reports that an estimated 5.2 million Americans suffered from Alzheimer's disease in 2013, and that by 2025 an estimated 7.1 million Americans will be afflicted by the disease, an approximate 40 percent increase from currently affected patients.

Cardiovascular Disease – Atherosclerosis, commonly referred to as a "hardening" or furring of the arteries, is the major underlying risk factor for CVD and heart attacks. WHO estimates 17 million people died from CVD in 2008 and more than 23 million will die annually of CVD by 2030.

CohBar is evaluating current drugs and pipelines of biotech/pharma across a spectrum of medical needs in order to determine the best market opportunities and target indications for CohBar's MBT's.

Type 2 Diabetes Worldwide Market (MOTS-c and Humanin Analogs)



Source: Evaluate Pharma, 2015

Obesity Worldwide Market (MOTS-c)



Source: Evaluate Pharma, 2015

Cancer Worldwide Markets (MOTS-c and SHLPs)

Prostate Cancer



Breast Cancer



Source: Evaluate Pharma, 2015

Alzheimer's Disease Worldwide Market (SHLPs)



Source: Evaluate Pharma, 2015

Cardiovascular Disease Worldwide Market (Humanin Analogs)



Source: Evaluate Pharma, 2015

CohBar Objectives

Selection of an MBT drug candidate:

- Evaluation of existing MDPs and any newly discovered MDPs
- Determination of initial activity in efficacy models
- Prioritization of potential lead molecules
- Synthesis of new analogs (MBTs)
- Iterative evaluation of stability, pharmacokinetics, and efficacy
- Selection of an MBT candidate for IND-enabling activities

Completion of IND-enabling activities:

- Preclinical testing (toxicology, safety pharmacology, genetic toxicity, pharmacokinetics)
- GMP manufacturing and stability of drug substance and formulation
- Filing and clearance of an Investigational New Drug (IND) application with the FDA to allow subsequent clinical trials

CohBar Business

Jon Stern (Chief Executive Officer)

CohBar 2014 – Statement of Operations

	For The Year Ended December 31, 2014
Revenues	$ -
Operating expenses:	
Research and development	579,474
General and administrative	1,233,141
Total operating expenses	1,812,615
Operating loss	(1,812,615)
Other income (expense):	
Interest income	593
Interest expense	(6,841)
Other expense	(488)
Amortization of debt discount	(333)
Total other income (expense)	(7,069)
Net loss	$ (1,819,684)
Basic and diluted net loss per share	$ (0.14)
Weighted average common shares outstanding - basic and diluted	12,915,343

CohBar Balance Sheet, 12/31/2014

	As of December 31, 2014
ASSETS	
Current assets:	
Cash	$ 1,194,492
Restricted cash	4,055
Prepaid expenses and other current assets	19,517
Total current assets	1,218,064
Property and equipment, net	4,631
Deferred offering costs	749,386
Other assets	1,100
Total assets	$ 1,973,181
LIABILITIES AND STOCKHOLDERS' EQUITY	
Current liabilities:	
Accounts payable	$ 290,073
Accrued liabilities	305,401
Accrued payroll and other compensation	103,294
Total current liabilities	698,768
Note payable, net of debt discount of $451 as of December 31, 2014	204,809
Total liabilities	903,577
Commitments and contingencies	
Stockholders'equity	
Preferred stock, $0.001 par value, Authorized- 8,000,000 shares; Issued and outstanding as of December 31, 2014:	
Preferred stock - Series A - issued and outstanding 0 shares as of December 31, 2014	-
Convertible preferred stock - Series B - issued and outstanding 5,400,000 shares as of December 31, 2014	5,400
Common stock, $0.001 par value, Authorized--37,000,000 shares; Issued and outstanding 12,915,343 shares as of December 31, 2014	12,915
Additional paid-in capital	5,507,616
Accumulated deficit	(4,456,327)
Total stockholders' equity	1,069,604
Total liabilities and stockholders' equity	$ 1,973,181

IPO, completed in January 2015, provided gross proceeds of $11.25M; concurrent with the IPO, CohBar completed a previously subscribed private placement for gross proceeds of $2.70M; total gross proceeds received was $13.95M.

Series B preferred converted to common shares upon IPO closing in January 2015.

Following the completion of the IPO and concurrent private placement, there were 32,290,891 shares of common stock outstanding in March 2015.

CohBar – 2014 Accomplishments

- **Research and Development:**
  CohBar Lab, CRO's, Academia

- **Management Team:**
  Search and hire of Ken Cundy (CSO)

- **Corporate Governance:**
  Expanded Board, Albion Fitzgerald and Marc Goldberg
  Engaged auditors, Marcum LLP (May)

- **Financing(s):**
  Series B Preferred (April)
  Engaged Haywood & Company as underwriters (August)
  Series B Puts (October)
  IPO Execution

- **Regulatory:**
  SEC and SEDAR filings

CohBar Operating Plan, 2015

Increasing investment in R&D

- New Laboratory and capital equipment
- Adding Scientific Staff: Hiring experienced scientists and lab technicians
- Establishing relationships with domain specific leading scientific consultants
- Expanding our academic research collaborations
- Increasing in-vitro and in-vivo activities with CRO's and academic partners

Increasing G&A Spending – corporate investment

- Expanding IP patent protection and international coverage
- Strategic marketing for CohBar's leadership in age-related diseases, MBTs
- Investor Relations, expanding shareholder base
- Public company compliance, regulatory filings

CohBar 1st Quarter 2015 Update

- Completed $11.25M IPO and concurrent $2.70M private placement
- Established new CohBar Lab in Menlo Park, California
- Initiated work under CohBar-USC Sponsored Research Agreement
- Engaged MacDougall Biomedical Communications for Corporate Strategy and Investor Relations
- Feature article on CohBar lead peptide MOTS-c authored by CohBar founder Dr. Cohen, published in Cell Metabolism magazine
- 2014 audit completed, 10-K filed

MOTS-c paper authored by Dr. Cohen and USC colleagues featured in Cell Metabolism



Major Findings for MOTS-c:

- Originates in mitochondria
- Regulates insulin sensitivity and metabolic homeostasis
- Counteracts insulin resistance - a critical feature of type-2 diabetes
- Prevents obesity in mice on a high fat diet

Article response:

- Time (online), BioCentury, Popular Science, Daily Mail, etc.,
- Top 2% of all Cell Metabolism articles ranked by attention
- UK, India-Asia, Argentina
- Twitter, Facebook

New CohBar Menlo Park Lab

- Ideal facility for early-stage companies
- Located close to Stanford and Silicon Valley biotech companies
- Initial 1500 square feet with space for expansion as needed
- Fully outfitting with equipment
- Pasadena lab relocated

CohBar Strategy

To build a multi-product company based on our expertise in MDP biology that, discovers, develops and commercializes first- and best-in-class mitochondria-based therapeutics (MBTs) for diseases with large unmet medical needs:

- Maintain our first mover advantage in MDP discovery and MBT therapeutics
- Exploit our MDP discoveries to date by advancing research and development and expanding our pipeline of MBT's
- Hire additional experienced scientists with proven track records to lead internal MBT development and management of external R&D collaborations and CRO relationships
- Expand our intellectual property portfolio of patents and licenses
- Leverage relationships with academic partners and contract research organizations (CROs)
- Develop strategic partnerships with larger pharmaceutical companies to support our research programs, future development and commercialization efforts

Projected Development Timeline and Milestones



Upcoming Shareholder Events

- Annual shareholder meeting on June 9, 2015 – virtual
- 2nd Quarter Investor call, TBA

Questions?

Meeting with Investors
Vancouver, B.C.
April 8, 2015